Literature DB >> 34410302

Aducanumab and the Business of Alzheimer Disease-Some Choice.

Jason Karlawish1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34410302     DOI： 10.1001/jamaneurol.2021.3123

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  3 in total

Review 1.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

2.  Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab.

Authors:  Emily A Largent; Andrew Peterson; Jason Karlawish; Holly Fernandez Lynch
Journal:  Drugs Aging       Date:  2022-06-13       Impact factor: 4.271

Review 3.  Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids.

Authors:  Manuel Torres; Sebastià Parets; Javier Fernández-Díaz; Roberto Beteta-Göbel; Raquel Rodríguez-Lorca; Ramón Román; Victoria Lladó; Catalina A Rosselló; Paula Fernández-García; Pablo V Escribá
Journal:  Membranes (Basel)       Date:  2021-11-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.